Skip to main
DTIL
DTIL logo

Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision Biosciences (DTIL) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Precision BioSciences Inc. exhibits a promising outlook driven by the encouraging initial data from its PBGENE-HBV program and the positive implications for its ARCUS platform, suggesting a de-risking of its in vivo gene editing pipeline. The company's collaboration with iECURE, which recently reported favorable first-in-infant data for the ECUR-506 program, enhances the validation of the ARCUS technology and underscores its potential in treating genetic disorders. With the anticipated advancements and robust preclinical data indicating a favorable safety profile, Precision's strategic position in genome editing may attract significant investor interest and support future growth.

Bears say

Precision BioSciences faces significant financial challenges stemming from the inherent risks associated with its novel gene editing platform, ARCUS, which may lead to long-term regulatory delays and safety concerns that can adversely affect clinical development timelines. The company is heavily reliant on its intellectual property for revenue generation, and any potential legal disputes or claims could further compromise its market position and profitability. Additionally, a negative scenario predicts that all of its pipeline programs could fail in clinical studies, severely impacting its future revenue prospects and overall market valuation.

Precision Biosciences (DTIL) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precision Biosciences (DTIL) Forecast

Analysts have given Precision Biosciences (DTIL) a Buy based on their latest research and market trends.

According to 9 analysts, Precision Biosciences (DTIL) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precision Biosciences (DTIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.